Abstract
Invasive fungal infections are of great concern in pediatric hematopoietic stem cell transplantation (HSCT) recipients. Voriconazole is usually the drug of first choice for treating or preventing invasive aspergillosis. Optimum trough levels (C(trough)s) are between 1 and 5 mg/liter. It is unclear whether these levels are reached with currently advised pediatric dosing schedules. Between 2007 and 2011, 11 patients 12 years) (P = 0.034). The intrapatient variability in C(trough) ranged between 1 and 238%. Voriconazole was discontinued in six patients due to toxicity. These patients had a median C(trough) of 0.5 mg/liter at the initial dose (ranging from 0.5 to 2.6 mg/liter), and a medium maximal concentration of 4 mg/liter was reached. Inter- and intrapatient variability is a major concern in voriconazole treatment and necessitates therapeutic drug monitoring of dosing, especially in young children.
Translated title of the contribution | Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. |
---|---|
Original language | Undefined/Unknown |
Pages (from-to) | 235-240 |
Number of pages | 6 |
Journal | Antimicrobial Agents and Chemotherapy |
Volume | 57 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2013 |